Sciwind Biosciences Completes Enrollment in Phase 2 Clinical Trial of XW003 in Type 2 Diabetes Patients

HANGZHOU, China and SAN FRANCISCO: HANGZHOU, China and SAN FRANCISCO, Dec. 9, 2021 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic disease, today announced the completion of patient enrollment in its Phase 2 clinical trial of XW003 in...

Click to view original post